EGFR and neoplasm: In vivo, Gefitinib and other EGFR-TKI drugs widely inhibit the tumor growth of human tumor cell derived lines xenografted in nude mice, and improve the anti-tumor activity of chemotherapy, radiotherapy and hormone therapy.